Alimera Sciences "Iluvien: Revolutioninzing DME Treatmen"t from OIS@AAO 2015

1. OIS Presentation
November 11, 2015

2. ILUVIEN: Revolutionizing DME Treatment

3. 3
The Only DME Treatment of its Kind
 Proven to last 36 months (12x
longer than next comparable long-
acting product)
 Continuous drug delivery
eliminates the inconsistent
treatment of other more frequently
dosed options
 Long term efficacy with a single
injection is patient friendly
Sustained, Multi-Year Approach to
Diabetic Macular Edema

4. 4
Debilitating, Permanent Effects of DME
• Primary cause of vision loss in diabetic
patients
• Leaky blood vessels in the macula cause
the retina to swell
• Causes blurred vision in early stage, over
long term may cause cumulative damage
Photo courtesy of Marinel Casiano CRA and Sanford Chen MD
of Orange County Retina.

5. 5
DME Patients Need More
BCVA 20/20,
15.0%
BCVA 20/40,
31.6%
BCVA 20/60
24.3%
BCVA 20/80
16.4%
BCVA 20/100
12.6%
Source: ASI MR June 2014
~55% of patients
end up 20/60
or worse
Based on Research with MD’s,
BCVA Levels Long Term
(2+ Years) That Their Patients
Achieve

6. 6
Visual Impact

7. 7
ILUVIEN Consistently Delivers
Months
ILUVIENPatientsWithImprovementinBCVAFrom
Baseline
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
0 3 6 9 12 15 18 21 24 27 30 33 36
≥ 1 Letter ≥ 1 Line ≥ 2 Line ≥ 3 Line
Please see ILUVIEN’s Full Prescribing information at www.ILUVIEN.com for important safety information.
Data shown from FAME Study.

8. What are the Doctors and Patients Saying?

9. 9
What are the Doctors and Patients
Saying?

10. Commercial Status

11. 11
ILUVIEN Launch Progress
France
SpainPortugal Italy
Ireland
U.K.
Germany Poland
Belgium
Denmark
Netherlands
Austria
Marketed Approved
CR
United States
CH

12. 12
License Deals
Canada
Australia
Israel

13. 13
Increasing Commercial Sales
Q3
2013
Q4
2013
Q1
2014
Q2
2014
Q3
2014
Q4
2014
Q1
2015
Q2
2015
Q3
2015
$758,000 $935,000
$2,100,000
$2,201,000
$2,408,000
$1,741,000
$3,938,000
$5,776,000
$6,910,000
Driving Towards Profitability

14. 14
J Code Available in January

15. 15
Innovation in Ophthalmology
ILUVIEN Geographic
Expansion
Patient Friendly
Products
Expanded ILUVIEN
Platform
Making a difference in patients lives by
becoming a leading provider in retina care

16. OIS Presentation
November 11, 2015